Pork company sales "sprint": More than 70% of the sales target completion rate exceeds 90%. December may continue to increase volume | Industry news.

① As of the end of November, over 70% of listed pork enterprises have exceeded 90% of their target for livestock output; ② Currently, smallholders and group pig farms are accelerating their output, leading to increased market supply of Pork, with limited strength in Animal Slaughter consumption, resulting in pork prices falling below 8 yuan; ③ The output of live pigs is expected to continue increasing in December.

cls.cnDec 11 02:39 ET

Jinyu bio-technology: The industry is in the lowest point in history. New products next year will contribute to revenue growth | Direct coverage of the earnings conference.

① At the performance briefing, the chairman of jinyu bio-technology, Zhang Chongyu, admitted that the industry is currently at its lowest point in history; ② The company stated that competition in the pig vaccine market is fierce, and it will maintain its existing market share. Several new vaccines will be launched in the next two years, and it is expected that the new products will contribute a certain revenue increment next year.

cls.cnNov 28 05:50 ET

Costs for 90% of pig enterprises have dropped to the range of 14 yuan: many companies say there is still room for cost reduction. Will profits stabilize next year? | Industry Observation

① 90% of the listed pork enterprises have reduced their costs to the range of 14 yuan per kilogram, including 5 enterprises such as Sunlon, Muyuan Foods, and Wens Foodstuff Group have reduced to the range of 13 yuan per kilogram; ② Many listed pork enterprises have indicated that there is still some room for cost reduction in the fourth quarter and next year; ③ Industry insiders believe that the cost reduction achievements have become the moat for the long-term development of pig enterprises. While helping companies expand profit margins, it also enhances the resilience of the companies against risks.

cls.cnNov 4 08:36 ET

Q3 net profit increased by more than 30 times year-on-year wens foodstuff group plans to distribute a large cash dividend of 0.995 billion yuan | interpretations

①Wens Foodstuff Group achieved a net income attributable to the parent company of 5.081 billion yuan in Q3, a year-on-year increase of 3097.03%; ②High pork prices, low costs, and increased sales volume drove the company's performance growth, with pork sales in the first three quarters increasing by 17.63% year-on-year and chicken sales increasing by 1.04% year-on-year; ③The company also announced a profit distribution plan on the same day, proposing to pay a generous cash dividend of 0.995 billion yuan.

cls.cnOct 22 10:48 ET

In the fourth quarter, the pig prices staged a "ultimate showdown" between bulls and bears, determining whether the pork industry will be "fat or lean" next year. | Industry Observations

1. The price of pork has been continuously falling for two months during the traditional strong period, with a decline of more than 20%; 2. Behind the decline is the increase in slaughter caused by the expansion of piglets and the concentrated slaughter in the second fattening, forming a downward momentum together; 3. If the pork price in the fourth quarter is not good during the peak season, the pig cycle may either rise directly or come to an end. If the pork price realizes an upward pig cycle, pig enterprises and the breeding industry are still expected to have a prosperous year in 2025.

cls.cnOct 22 06:40 ET

Shanghai Shen Lian Biomedical Corporation: Intensified competition weakens the leading profit of pig vaccines, will expand new product development | Directly hit earnings conference

1. Affected by the sluggish downstream livestock breeding market and price decline, the leading pig vaccine maker Shanghai Shen Lian Biomedical Corporation experienced an increase in revenue but not in profit; 2. Nie Dongsheng stated at the earnings conference that in the second half of 2024, Shanghai Shen Lian Biomedical Corporation will timely adjust short-term, medium-term, and long-term operating goals, expand market development and global strategic layout of new products, including cattle and sheep foot-and-mouth disease inactivated vaccines, increase the sales proportion of pig circovirus vaccines, and at the same time, have products entering the supply chain system of multiple large-scale breeding groups.

cls.cnOct 21 06:34 ET